Clinical trial
CHOP-Rituximab Augmented With GM-CSF in Patients With Previously Untreated…
NCT00455897 · Massachusetts General Hospital, Other · Terminated
Key facts
| NCT number | NCT00455897 |
|---|---|
| Title | CHOP-Rituximab Augmented With GM-CSF in Patients With Previously Untreated Diffuse Large B Cell Non-Hodgkin's Lymphoma |
| Official title | Phase II Trial of CHOP-Rituximab Augmented With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Previously Untreated Diffuse Large B Cell Non-Hodgkin's Lymphoma |
| Lead sponsor | Massachusetts General Hospital, Other |
| Collaborators | Beth Israel Deaconess Medical Center Brigham and Women's Hospital Dana-Farber Cancer Institute Bayer Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma, Non-Hodgkin, B-Cell, Diffuse |
| Intervention type | Drug |
| Interventions | GM-CSF, CHOP, Rituximab |
| Enrollment | 3 |
| Start date | Dec 1, 2006 |
| Primary completion | Nov 1, 2007 |
| Completion | Jul 1, 2011 |
| First posted | Apr 4, 2007 |
| Last update posted | Jan 18, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: